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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of the informant-based questionnaire AD-8, in detection of all-cause (undifferentiated) dementia in
adults. We will present data for each healthcare setting where AD-8 may be employed (community; primary care; secondary care).
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B A C K G R O U N D
Dementia is a substantial and growing public health concern
(Hebert 2013; Prince 2013). As an example, depending on case defi-
nition employed, contemporary estimates of dementia prevalence
in the United States are in the range 2.5 to 4.5 million individu-
als (1.6% population at higher rate; 6.5% of those aged over 65).
Changes in population demographics will be accompanied by in-
creases in global dementia incidence and prevalence (Ferri 2005).
Although the magnitude of the increase in prevalent dementia may
have been overestimated in previous prediction models (Matthews
2013), there is no doubt that absolute numbers of older adults with
dementia will increase substantially in the short- to medium-term
future (Ferri 2005).
A key element of effective management in dementia is a firm diag-
nosis. Recent guidelines place emphasis on early diagnosis to fa-
cilitate improved management and to allow informed discussions
and planning with patients and carers. The benefits of screening
for cognitive decline are debated (Brunet 2012); however in certain
healthcare systems screening or case-finding has already been in-
troduced for certain groups, e.g. unscheduled hospital admissions
of older adults (Shenkin 2014).
Given the projected global increase in dementia prevalence, there
is a potential tension between the clinical requirements for robust
diagnosis at the individual patient level and the need for equitable,
easy access to diagnosis at a population level. The ideal would be
expert, multidisciplinary assessment informed by various supple-
mentary investigations (neuropsychology; neuroimaging or other
biomarkers). This approach is only really feasible in a specialist
memory service and is not suited to population screening or case-
finding.
In practice a two-stage process is often employed - with initial
'triage' assessments, suitable for use by non-specialists - to se-
lect those who require second-stage, further detailed assessment
(Boustani 2003).
Various tools for initial cognitive screening have been described
(Brodaty 2002; Folstein 1975; Galvin 2005). Regardless of the meth-
ods employed, there is scope for improvement, with observational
work suggesting that many with dementia are not diagnosed (Cho-
dosh 2004; Valcour 2000).
Screening assessment often takes the form of brief, direct cogni-
tive testing. Such an approach will only provide a 'snapshot' of cog-
nitive function. However, a defining feature of dementia is cogni-
tive or neuropsychological change over time. People with cogni-
tive problems themselves may struggle to make an objective as-
sessment of personal change and so an attractive approach is to
question collateral sources with sufficient knowledge of the per-
son. These informant-based interviews aim to retrospectively as-
sess change in function.
An instrument prevalent in research and clinical practice, partic-
ularly in North America, is the eight-item Informant Interview to
differentiate Ageing and Dementia (AD-8) and this screening/triage
tool will be the focus of this review.
A number of properties can be described for a clinical assess-
ment (reliability, responsiveness, feasibility). For our purposes the
test property of greatest interest is diagnostic test accuracy (DTA)
(Cordell 2013).
Although we will describe test accuracy of AD-8 for dementia diag-
nosis, AD-8 used in isolation is not suitable for establishing a clini-
cal dementia diagnosis. AD-8 is a triage tool, suitable for selecting
those who require more definitive assessment.
Target condition being diagnosed
The target condition for this diagnostic test accuracy review is all-
cause dementia (clinical diagnosis) (Appendix 1).
Dementia is a syndrome characterised by cognitive or neuropsy-
chological decline sufficient to interfere with usual functioning.
The neurodegeneration and clinical manifestations of dementia
are progressive and at present there is no 'cure', although numer-
ous pharmacological (Birks 2006; McShane 2006) and non-pharma-
cological interventions (Bahar-Fuchs 2013) to slow or arrest cogni-
tive decline have been described.
Dementia remains a clinical diagnosis, based on history from the
person and suitable collateral sources and direct examination, in-
cluding cognitive assessment. There is no universally-accepted,
ante-mortem, gold-standard diagnostic strategy. We have chosen
expert clinical diagnosis as our gold standard (reference standard)
for describing AD-8 test properties, as we believe this is most in
keeping with current diagnostic criteria and best practice.
Dementia diagnosis can be made according to various internation-
ally-accepted diagnostic criteria, with exemplars being the World
Health Organization, International Classification of Diseases (ICD)
ICD-10 and the American Psychiatric Association Diagnostic and
Statistical Manual of Mental Disorders (DSM) DSM-IV for all-cause
dementia and subtypes (Appendix 1). The label of dementia en-
compasses varying pathologies, of which Alzheimer’s disease is the
most common. Diagnostic criteria are available for specific demen-
tia subtypes, i.e. NINCDS-ADRDA criteria for Alzheimer’s dementia
(McKhann 1984; McKhann 2011); McKeith criteria for Lewy Body de-
mentia (McKeith 2005); Lund criteria for frontotemporal dementias
(McKhann 2001); and the NINDS-AIREN criteria for vascular demen-
tia (Román 1993).
Index test(s)
Our index test will be the Alzheimer Disease 8 (AD-8) (Galvin 2005)
(Appendix 2; Appendix 3).
First published in 2005, the AD-8 is a screening tool which has been
used to distinguish individuals with normal cognitive function from
those with dementia or mild cognitive impairment. It is designed
to be administered to a relevant proxy, usually a relative or carer,
in questionnaire form. The AD-8 is a brief screening tool. With on-
ly eight questions it takes less than three minutes to complete and
was developed to replace other lengthy informant questionnaires
(Galvin 2006). The AD-8 was originally developed for administra-
tion in the English language but has been reproduced in other lan-
guages including Brazilian Portuguese (Correia 2011),Taiwanese
(Yang 2011), and Korean (Ryu 2009).
The AD-8 items cover domains of judgement, hobby/activity lev-
el, repetitive conversations, learning ability, memory in relation to
date/appointments, finances and daily thought processes. Infor-
mants indicate presence of change “over several years” using re-
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sponses of ‘Yes, a change’, ‘No, no change’ or ‘NA, don’t know’. Each
'yes' answer is scored one point, giving scores ranging from ze-
ro, where no change has been noticed by the informant, to eight,
where change has been noted across all domains. The commonly
employed threshold score for AD-8 to differentiate cognitive from
no cognitive impairment is greater than or equal to two out of eight
(i.e. a 'yes' response for two or more items) (Galvin 2005).
AD-8 has a number of features that make it attractive for clinical
and research use. The questions used have an immediacy and rele-
vance that is likely to appeal to users. Assessment and (informant)
scoring is brief, and as the scale is not typically interviewer-adminis-
tered it requires minimal training in application and scoring. There
are data to suggest that, compared to standard direct assessments,
informant interviews may be less prone to bias from cultural norms
and previous level of education (Jorm 2004). New diagnostic cri-
teria for dementia make explicit reference to documenting decline
and involving collateral informants, emphasising the potential util-
ity of an informant interview tool such as AD-8.
Clinical pathway
Dementia develops over a trajectory of several years and screening
tests may be performed at different stages in the dementia path-
way. In this review we will consider any use of AD-8 as an initial as-
sessment for cognitive decline and we will not limit to a particu-
lar healthcare setting. We have operationalised the various settings
where AD-8 may be used as secondary care, primary care, and com-
munity.
In secondary-care settings, patients will have been referred for ex-
pert input but not exclusively due to memory complaints. Cognitive
testing in secondary care involves two main groups: opportunistic
screening of adults presenting as unscheduled admissions to hos-
pitals, and those people referred to specific dementia, memory or
psychiatry of older age services. Both populations will have a high
prevalence of cognitive disorders and mimics. Secondary-care pa-
tients are more likely to have had a degree of prior cognitive assess-
ment than those in other settings, although we recognise that cog-
nitive screening prior to referral to specialist services is neither con-
sistent nor guaranteed (Menon 2011).
In the general practice/primary care setting, the person will self
present to a non-specialist service because of subjective memory
complaints. There is unlikely to have been previous cognitive test-
ing but prevalence of disease may be reasonably high. Using AD-8
in this setting could be described as 'triage' or 'case-finding'.
In the community setting, the cohort is largely unselected and the
approach may be described as 'population screening'.
Most studies of test accuracy compare the test against contempo-
raneous reference standards (in this case, clinical dementia diag-
nosis). An alternative is to describe the test properties for detection
of early, 'pre-clinical' problems that are formally diagnosed during
prospective, longitudinal follow-up. This delayed verification ap-
proach is commonly employed in studies describing properties of
dementia biomarkers, but may have utility for other test strategies
such as informant interview.
Rationale
There is no consensus on the optimal initial assessment for demen-
tia, and choice is currently dictated by experience with a particular
instrument, time constraints and training. A better understanding
of the diagnostic properties of various strategies would allow for an
informed approach to testing. Critical evaluation of the evidence
base for screening tests or other diagnostic markers is of major im-
portance. Without a robust synthesis of the available information
there is the risk that future research, clinical practice and policy will
be built on erroneous assumptions about diagnostic validity.
AD-8 is commonly used in practice and research; it is used interna-
tionally and is one of only a few validated informant-based screen-
ing/diagnostic tools. A literature describing the test accuracy of
AD-8 in different settings is available, although some of these stud-
ies have been modest in size. Thus systematic review and, if possi-
ble, meta-analysis of the diagnostic properties of AD-8 is warranted.
This review will form part of a body of work describing the diagnos-
tic properties of commonly-used dementia tools (Appendix 4). At
present we are conducting single-test reviews and meta-analyses.
However the intention is then to collate these data, performing an
overview allowing comparison of various test strategies.
O B J E C T I V E S
To determine the diagnostic accuracy of the informant-based ques-
tionnaire AD-8, in detection of all-cause (undifferentiated) demen-
tia in adults. We will present data for each healthcare setting where
AD-8 may be employed (community; primary care; secondary care).
Secondary objectives
Where data are available, we will describe the following:
1. Accuracy of AD-8 for early detection of cognitive problems, where
a later diagnosis of dementia is made (delayed verification diagno-
sis).
2. Effects of heterogeneity on the reported diagnostic accuracy of
AD-8. Potential sources of heterogeneity that we will explore in-
clude: case mix of cohort; method of dementia diagnosis; method
AD-8 assessment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We anticipate that the majority of studies will be of AD-8 test prop-
erties compared against a contemporaneous clinical diagnosis of
dementia in secondary care settings. We will include test studies
performed in other healthcare settings and classify these as: 'pri-
mary care' or 'community'. We will include studies that use a de-
layed verification methodology but will perform a separate analy-
sis for this study design.
Case-control studies are known to potentially overestimate prop-
erties of a test and we will not include such studies in this review.
We will not include case studies or samples with very small num-
bers (chosen as 10 participants, for the purposes of this review).
There may be cases where settings are mixed, for example, a popu-
lation study 'enriched' with additional cases from primary care. We
will consider separate data from each setting if available. If these
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
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data are not available we will treat these studies as case-control
and will exclude them.
Participants
All adults (aged over 18 years) will be eligible.
We have not predefined exclusion criteria relating to the 'case-mix'
of the population studied, but will assess this aspect of the study
as part of our assessment of heterogeneity. Where there is concern
that the participants are not representative of a primary care sam-
ple, we will explore this at study level using the 'Risk of bias' assess-
ment framework outlined below.
Index tests
Studies must include (not necessarily exclusively) AD-8 used as an
informant questionnaire.
AD-8 has been translated into various languages to allow interna-
tional administration. The properties of a translated AD-8 in a co-
hort of non-English speakers may differ from properties of the origi-
nal English language questionnaire. We will collect data on the prin-
cipal language used for AD-8 assessment.
For this review we will not consider other cognitive screening/as-
sessment tools. Where a paper describes AD-8 with in-study com-
parison against another screening tool, we will include the AD-8 da-
ta only. Where AD-8 is used in combination with another cognitive
screening tool, we will include the AD-8 data only.
Target conditions
We will include any clinical diagnosis of all-cause (unspecified) de-
mentia. We will not require defining of a particular dementia sub-
type, although where available we will record these data.
Reference standards
Our reference standard will be clinical diagnosis of dementia. We
recognise that clinical diagnosis itself has a degree of variability but
this is not unique to dementia studies and does not invalidate the
basic diagnostic test accuracy approach.
Primary analysis will be for clinical diagnosis to include all-cause
(unspecified) dementia, using any recognised diagnostic criteria
(for example, ICD-10; DSM-IV ICD-10 DSM-IV). Dementia diagno-
sis may specify a pathological subtype and we will include all
common dementia subtypes (e.g. NINCDS-ADRDA (Alzheimer's Dis-
ease), Lund-Manchester (Frontotemporal dementia), McKeith (De-
mentia with Lewy Bodies), NINCDS-AIREN (Vascular dementia);
McKeith 2005; McKhann 1984; McKhann 2001; Román 1993). We
have not defined preferred diagnostic criteria for rarer forms of
dementia (e.g. alcohol-related; HIV-related; prion disease-related).
We will consider these under our rubric of 'all-cause' dementia, and
will not consider them separately.
The label 'dementia' can also span a range of disease severities,
from mild disease to 'end stage'. The diagnostic properties of a tool
will vary depending on disease stage, for example, true positives
are more likely when disease is advanced and diagnosis is clear. For
our primary analysis we will include any dementia diagnosis at any
stage of disease.
Clinicians may use imaging, pathology or other data to aid diagno-
sis; however, we will not include diagnosis based only on these da-
ta without corresponding clinical assessment. We recognise that
different iterations of diagnostic criteria may not be directly com-
parable and that diagnosis may vary with the degree or manner in
which the criteria have been operationalised (e.g. individual clin-
ician versus algorithm versus consensus determination). We will
collect data on method and application of dementia diagnosis for
each study, and will explore potential effects as part of our assess-
ment of heterogeneity. We will not accept use of other (brief) direct
performance tests in isolation as a basis for diagnosis.
We recognise that dementia diagnosis often comprises a degree
of informant assessment. Thus there is potential for incorporation
bias. We will explore the potential effects of this bias through our
'Risk of bias' assessment.
Search methods for identification of studies
We will use a variety of information sources to ensure all relevant
studies are included. We will devise terms for electronic database
searching in conjunction with the team at the Cochrane Demen-
tia and Cognitive Improvement Group. As this AD-8 review forms
part of a suite of reviews looking at informant scales we have creat-
ed a comprehensive search strategy designed to pick up all cogni-
tive assessment scales Quinn 2014; we will complement this gener-
ic search with searches specific to AD-8 terminology.
Electronic searches
We will search the specialised register of the Cochrane Dementia
and Cognitive Improvement Group, ALOIS (which includes both in-
tervention and diagnostic accuracy studies), MEDLINE (Ovid SP),
EMBASE (Ovid SP), BIOSIS (Web of Knowledge), Science Citation In-
dex (ISI Web of Knowledge), PsycINFO (Ovid SP), CINAHL (EBSCO-
host) and LILACS (Bireme). See Appendix 5; Appendix 6 for a pro-
posed draH strategy to be run in MEDLINE (Ovid SP) along with
a narrative describing how the strategy was developed and val-
idated. We will design similarly-structured search strategies us-
ing search terms appropriate to each database. We will use MeSH
words and other controlled vocabulary where appropriate.
We will also search sources specific to diagnostic accuracy or sys-
tematic review:
· MEDION database (Meta-analyses van Diagnostisch Onderzoek
www.mediondatabase.nl);
· DARE (Database of Abstracts of Reviews of Effects) and HTA
Database (Health Technology Assessments Database), both The
Cochrane Library;
· ARIF database (Aggressive Research Intelligence Facility;
www.arif.bham.ac.uk).
We will apply no language or date restrictions to the electronic
searches and will operate no restrictions by publication status; as-
sessing for potential inclusion: abstracts, conference proceedings
and unpublished data. We will use translation services as neces-
sary.
The Cochrane Dementia and Cognitive Impairment Group Trials
Search Co-ordinator will run the initial searches.
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
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Searching other resources
Grey literature and proceedings: chosen electronic databases in-
clude assessments of conference proceedings. We will aim to ac-
cess theses or PhD abstracts from institutions known to be involved
in prospective dementia studies.
Handsearching: We will not perform handsearching as there is little
published evidence of the benefits of handsearching for diagnostic
studies (Glanville 2010).
Reference lists: We will check the reference lists of all relevant stud-
ies and reviews in the field for further possible titles and will repeat
the process until no new titles are found (Greenhalgh 2005).
Correspondence: We will contact research groups who have pub-
lished or are conducting work on AD-8 for dementia diagnosis, in-
formed by results of initial search.
We will use relevant studies in PubMed to search for additional
studies using the 'Related article' feature. We will examine key stud-
ies in citation databases such as Science Citation Index and Scopus
to ascertain any further relevant studies.
Data collection and analysis
Selection of studies
Two review authors will independently screen all titles generated
by electronic database searches for relevance. Two review authors
will inspect abstracts of selected titles and will select all potential-
ly eligible studies for full-paper review. Two review authors will in-
dependently assess full manuscripts against the inclusion criteria,
resolving disagreement by discussion, or by involving an arbitrator
if necessary.
Where a study may include useable data but these are not present-
ed in the published manuscript, we will contact the authors direct-
ly to request further information. If the same data are presented in
more than one paper we will include the primary paper only.
We will detail the study selection process in a PRISMA flow diagram.
Data extraction and management
We will extract data to a study-specific pro forma that includes clin-
ical/demographic details of the participants; details of setting; de-
tails of AD-8 administration and details of the dementia diagnosis
process.
We will extract test accuracy data to a standard two-by-two table.
Two review authors, blinded to study identifiers, will perform da-
ta extraction independently, resolving disagreement by discussion,
with the use of an arbitrator if necessary.
For each included paper, we will detail the flow of participants
(numbers recruited, included, assessed) in a flow diagram.
Assessment of methodological quality
As well as describing test accuracy, an important goal of the DTA
process is to improve study design and reporting in dementia diag-
nostic studies. For this reason we will assess methodological and
reporting quality using two complementary processes.
We will assess the quality of study reporting using the STARD check-
list (Bossuyt 2003) (Appendix 7). If it becomes available during the
course of the review, we will use the proposed dementia-specific
extension to the STARD tool - STARDdem (starddem.org/). We will
tabulate and present STARD data as an appendix to the review.
We will assess the methodological quality of each study using
the QUADAS-2 tool (www.bris.ac.uk/quadas/quadas-2).(Appendix
8) This tool incorporates domains specific to participant selection;
index test; reference standard; and participant flow. Each domain
is assessed for risk of bias and the first three domains are also as-
sessed for applicability. Certain key areas important for quality as-
sessment are participant selection; blinding; and missing data. Fol-
lowing a group meeting of review authors, we created guidance for
the application of QUADAS-2 to dementia screening assessments,
specifically developing anchoring statements for QUADAS-based
assessment that are suited to dementia test accuracy studies. This
QUADAS-2 guidance was created through a multidisciplinary work-
ing group and has been extensively piloted. The process and result-
ing statements for assessment are described in Appendix 9.
We will not use QUADAS-2 data to form a summary quality score,
but will produce a narrative summary describing numbers of stud-
ies that found high/low/unclear risk of bias/concerns regarding ap-
plicability with corresponding tabular and graphical displays.
Paired independent raters, blinded to each other’s scores, will per-
form both assessments, resolving disagreement by further review
and discussion, with recourse to a third party arbitrator where nec-
essary.
Statistical analysis and data synthesis
We are interested in the test accuracy of AD-8 for the dichotomous
variable 'dementia'/'no dementia'. Thus, we will apply the current
Cochrane DTA framework for analysis of a single test. We will extract
data from included papers to allow creation of a standard two-by-
two data table showing dichotomised AD-8 test results (AD-8 pos-
itive or AD-8 negative) cross-classified with binary reference stan-
dard (dementia or no dementia).
We will use Review Manager 5 software (RevMan 2012) to calculate
sensitivity, specificity and 95% confidence intervals (CIs) from the
two-by-two tables abstracted from the included studies. We will
use a threshold score of two or more on AD-8 for primary analyses.
If data at other thresholds are presented we will examine these in
separate analyses. We will present individual study results graphi-
cally by plotting estimates of sensitivities and specificities as forest
plots.
To allow for summary analysis, we will use software additional to
RevMan (SAS release 9.1). Using the bivariate approach we will de-
scribe metrics of pooled sensitivity, specificity, positive and neg-
ative predictive values; positive and negative likelihood ratios, all
with corresponding 95% confidence intervals. We will plot summa-
ry data in receiver operating characteristic (ROC) space, including
95% confidence and prediction regions.
We suspect papers will use the classical cross-sectional test accu-
racy study design. An alternative is the 'delayed verification' study
design, i.e. AD-8 is performed at baseline and those without disease
are prospectively followed up for development of incident demen-
tia. If any papers use this methodology, we will use baseline (con-
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
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temporaneous testing) data for our primary analysis; we will not de-
scribe data based on prospective testing separately.
Investigations of heterogeneity
Heterogeneity is expected in DTA reviews and 'traditional' mea-
sures of heterogeneity used in meta-analysis are not appropriate to
DTA reviews.
The properties of a tool describe behaviour of the instrument under
particular circumstances. We will include all AD-8 studies in narra-
tive review. We have prespecified particular areas of potential het-
erogeneity.
Healthcare setting
We suspect that healthcare setting will impact on properties of the
test and we will restrict our primary analyses to the various prede-
fined healthcare settings. Based on the spread of data, review au-
thors will decide if a pooled analysis including all healthcare set-
tings is valid. If we conduct it, we will clearly label this analysis as
a secondary analysis.
Case mix
In the first instance we will explore age, taking age over 65 years as
a reference point. We suspect that the majority of included partici-
pants in eligible studies will be aged over 65 years. AD-8 may have
different properties in younger cohorts and so we will look at age
ranges within studies. We will grade studies that have greater than
20% of included participants younger than 65 years as potentially
unrepresentative, and will run sensitivity analyses assessing the ef-
fect on summary parameters of removing these studies.
We anticipate that most studies will be of unselected adults. How-
ever, studies may limit inclusion to a specific population, for exam-
ple, stroke survivors. Again, we will run sensitivity analyses assess-
ing the effect on summary parameters of removing these studies.
If data allow, we will also explore case mix within the dementia di-
agnosis, performing subgroup or sensitivity analyses for various de-
mentia pathological subtypes.
Clinical criteria used to reach dementia diagnosis
We will record the classification used (for example ICD-10; DSM-
IV ICD-10 DSM-IV ) and the methodology used to reach dementia
diagnosis (for example, individual assessment; group (consensus)
assessment). We will assess the 'quality' of diagnosis at study lev-
el using the QUADAS-2 tool. If data allow, we will compare sub-
groups, describing summary statistics for each group, for example
ICD-based diagnosis versus DSM-based diagnosis; individual clini-
cian versus group adjudication.
Technical features of the testing strategy
Our focus will be on language of assessment. In the first instance we
will classify as English language and non-English language tests. We
will perform subgroup analyses comparing English language AD-8
versus non-English language AD-8.
We do not anticipate that AD-8 will be used at differing thresholds.
If papers describe a range of AD-8 cut-points we will explore this
using HSROC techniques, with cut-points as covariates.
Sensitivity analyses
Where appropriate (i.e. if not already explored in our analyses of
heterogeneity) and as data allow, we will explore the sensitivity of
any summary accuracy estimates to aspects of study quality such
as nature of blinding and loss to follow-up, guided by the anchoring
statements developed in our QUADAS-2 exercise. Primary analy-
sis will include all eligible studies, while sensitivity analysis will ex-
clude studies of low quality (high likelihood of bias) to determine if
the results are influenced by inclusion of the lower-quality studies.
Assessment of reporting bias
We will not investigate reporting bias because of current uncertain-
ty about how it operates in test accuracy studies, and about the in-
terpretation of existing analytical tools such as the funnel plot.
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
R E F E R E N C E S
 
Additional references
Bahar-Fuchs 2013
Bahar-Fuchs A, Clare L, Woods B. Cognitive training
and cognitive rehabilitation for mild to moderate
Alzheimer's disease and vascular dementia. Cochrane
Database of Systematic Reviews 2013, Issue 6. [DOI:
10.1002/14651858.CD003260.pub2]
Birks 2006
Birks J. Cholinesterase inhibitors for Alzheimer's disease.
Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI:
10.1002/14651858.CD005593]
Bossuyt 2003
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP,
Irwig LM, et al. Standards for Reporting of Diagnostic
Accuracy. Towards complete and accurate reporting of
studies of diagnostic accuracy: The STARD initiative. BMJ
2003;326(7379):41-4.
Boustani 2003
Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening
for dementia in primary care: a summary of the evidence for the
US Preventative Services Task Force. Annals of Internal Medicine
2003;138(11):927-37.
Brodaty 2002
Brodaty H. The GPCOG: a new screening test for dementia
designed for general practice. Journal of the American Geriatrics
Society 2002;50(3):530-4.
Brunet 2012
Brunet MD, McCartney M, Heath I, Tomlinson J, Gorodon P,
Cosgrove J, et al. There is no evidence base for proposed
dementia screening. BMJ 2012;345:e8588.
Chodosh 2004
Chodosh J, Petitti DB, Elliott M, Hays RD, Crooks VC, Reuben DB,
et al. Physician recognition of cognitive impairment: evaluating
the need for improvement. Journal of the American Geriatrics
Society 2004;52(7):1051-9.
Cordell 2013
Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D,
Verghese J, et al. Medicare Detection of Cognitive Impairment
Workgroup. Alzheimer's Association recommendations for
operationalizing the detection of cognitive impairment during
Medicare Annual Wellness Visit in a primary care setting.
Alzheimer's & Dementia 2013;9(2):141-50.
Correia 2011
Correia CC, Lima F, Junqueira F, Campos MS, Bastos O,
Petribu K, et al. AD8-Brazil: cross-cultural validation of the
ascertaining dementia interview in Portuguese. Journal of
Alzheimer's Disease 2011;27(1):177-85.
Davis 2013
David HJD, Creavin ST, Noel-Storr A, Quinn TJ, Smailagic N,
Hyde C, Brayne C, McShane R, Cullum S. Neuropsychological
tests for the diagnosis of Alzheimer's disease dementia
and other dementias: a generic protocol for cross-sectional
and delayed verification studies.. Cochrane Database
of Systematic Reviews 2013, Issue 4; CD010460. [DOI:
10.1002/14651858.CD010460]
DSM-IV
American Psychiatric Association. Diagnostic and statistical
manual of mental disorders (4th Ed). Washington DC: American
Psychiatric Association, 2000.
Ferri 2005
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L,
Ganguli M, et al. Alzheimer's Disease International. Global
prevalence of dementia: a Delphi consensus study. Lancet
2005;366(9503):2112-7.
Folstein 1975
Folstein MF, Folstein SE, McHugh PR. "Minimental state": a
practical method for grading the cognitive state of patients for
the clinician. Journal of Psychiatric Research 1975;12(3):189-98.
Galvin 2005
Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E,
et al. The AD8: A brief informant interview to detect dementia.
Neurology 2005;65(4):559-64.
Galvin 2006
Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability
of the AD8 informant interview in dementia.. Neurology
2006;67(11):1942-8.
Glanville 2010
Glanville JM, Cikalo M, Crawford F, Dozier M, Lowson P.
Handsearching for reports of diagnostic test accuracy studies
adding to the evidence base.. Joint Cochrane and Campbell
Colloquium, Madrid, Spain. 2010.
Greenhalgh 2005
Greenhalgh T, Peacock R. E=ectiveness and e=iciency of search
methods in systematic reviews of complex evidence. BMJ
2005;331(7524):1064-5.
Hebert 2013
Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in
the United States (2010-2050) estimated using the 2010 census.
Neurology 2013;80(19):1778-83.
ICD-10
World Health Organisation. International Classification of
Diseases (ICD) 10th Edition. WHO, 1992.
Jorm 2004
Jorm AF. The Informant Questionnaire on cognitive decline in
the elderly (IQCODE): a review. International Psychogeriatrics
2004;16(3):275-93.
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Matthews 2013
Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L,
et al. A two-decade comparison of prevalence of dementia in
individuals aged 65 and older from three geographical areas of
England: results of the Cognitive Function and Ageing Study I
and II. Lancet 2013;382(9902):1405-12.
McKeith 2005
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H,
et al. Diagnosis and management of dementia with Lewy
bodies: third report of the DLB Consortium. Neurology
2005;65(12):1863-72.
McKhann 1984
McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer's disease: report
of the NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on
Alzheimer's Disease. Neurology 1984;34(7):939-44.
McKhann 2001
McKhann GM, Albert MS, Grossman M, Miller B, Dickson D,
Trojanowski JQ: Work Group on Frontotemporal dementia
and PIck’s disease. Clinical and pathological diagnosis of
frontotemporal dementia: report of the Work Group on
Frontotemporal Dementia and Pick's Disease. Archives of
Neurology 2001;58(11):1803-9.
McKhann 2011
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s
disease:recommendations from the National Institute on Aging
- Alzheimer’s Association workgroup on diagnostic guidelines
for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263-9.
McShane 2006
McShane R, Areosa Sastre A, Minakaran N. Memantine for
dementia. Cochrane Database of Systematic Reviews 2006, Issue
2. [DOI: 10.1002/14651858.CD003154]
Menon 2011
Menon R, Larner AJ. Use of cognitive screening instruments in
primary care: the impact of national dementia directives. Family
Practice 2011;28(3):272-6..
Prince 2013
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP.
The global prevalence of dementia: a systematic review and
metaanalysis. Alzheimer's and Dementia 2013;9(1):63-75.
Quinn 2014
Quinn TJ, Fearon P, Noel-Starr A, Young C, McShane R, Stott DJ.
Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE) for the diagnosis of dementia within community
dwelling populations. Cochrane Database of Systematic Reviews
2014, Issue 4. [DOI: 10.1002/14651858.CD010079.pub2]
RevMan 2012 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.2. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Román 1993
Román GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masdeu JC,
Garcia JH, et al. Vascular dementia: diagnostic criteria for
research studies. Report of the NINDS-AIREN International
Workshop. Neurology 1993;43(2):250-60.
Ryu 2009
Ryu HJ, Kim HJ, Han SH. Validity and reliability of the Korean
version of AD8 informant interview (K-AD8) in dementia.
Alzheimer Disease and Associated Disorders 2009;23(4):371-6.
Shenkin 2014
Shenkin SD, Russ TC, Ryan TM, MacLullich AM. Screening for
dementia and other causes of cognitive impairment in general
hospital inpatients. Age and Ageing 2014;43(2):166-8.
Valcour 2000
Valcour VG, Masaki KH, Curb JD, Blanchette PL. The detection
of dementia in the primary care setting. Archives of Internal
Medicine 2000;160(19):2964-8.
Yang 2011
Yang YH, Galvin JE, Morris JC, Lai CL, Chou MC, Liu CK.
Application of AD8 questionnaire to screen very mild dementia
in Taiwanese. American Journal of Alzheimers Disease and Other
Dementias 2011;26(2):134-8.
 
A P P E N D I C E S
Appendix 1. WHO International Classification of Disease - Dementia
World Health Organization International Classification of Diseases 10
F00 - F09 ORGANIC, INCLUDING SYMPTOMATIC, MENTAL DISORDERS
DEMENTIA
G1. Evidence of each of the following:
(1) A decline in memory, which is most evident in the learning of new information, although in more severe cases, the recall of previously
learned information may be also affected. The impairment applies to both verbal and non-verbal material. The decline should be objec-
tively verified by obtaining a reliable history from an informant, supplemented, if possible, by neuropsychological tests or quantified cog-
nitive assessments. The severity of the decline, with mild impairment as the threshold for diagnosis, should be assessed as follows:
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Mild: a degree of memory loss sufficient to interfere with everyday activities, though not so severe as to be incompatible with independent
living. The main function affected is the learning of new material. For example, the individual has difficulty in registering, storing and
recalling elements in daily living, such as where belongings have been put, social arrangements, or information recently imparted by family
members.
Moderate: A degree of memory loss which represents a serious handicap to independent living. Only highly learned or very familiar material
is retained. New information is retained only occasionally and very briefly. The individual is unable to recall basic information about where
he lives, what he has recently been doing, or the names of familiar persons.
Severe: a degree of memory loss characterized by the complete inability to retain new information. Only fragments of previously learned
information remain. The subject fails to recognize even close relatives.
(2) A decline in other cognitive abilities characterized by deterioration in judgement and thinking, such as planning and organizing, and in
the general processing of information. Evidence for this should be obtained when possible from interviewing an informant, supplemented,
if possible, by neuropsychological tests or quantified objective assessments. Deterioration from a previously higher level of performance
should be established. The severity of the decline, with mild impairment as the threshold for diagnosis, should be assessed as follows:
Mild. The decline in cognitive abilities causes impaired performance in daily living, but not to a degree making the individual dependent
on others. More complicated daily tasks or recreational activities cannot be undertaken.
Moderate. The decline in cognitive abilities makes the individual unable to function without the assistance of another in daily living, in-
cluding shopping and handling money. Within the home, only simple chores are preserved. Activities are increasingly restricted and poorly
sustained.
Severe. The decline is characterized by an absence, or virtual absence, of intelligible ideation. The overall severity of the dementia is best
expressed as the level of decline in memory or other cognitive abilities, whichever is the more severe (e.g. mild decline in memory and
moderate decline in cognitive abilities indicate a dementia of moderate severity).
G2. Preserved awareness of the environment during a period of time long enough to enable the unequivocal demonstration of G1. When
there are superimposed episodes of delirium the diagnosis of dementia should be deferred.
G3. A decline in emotional control or motivation, or a change in social behaviour, manifest as at least one of the following:
(1) emotional lability;
(2) irritability;
(3) apathy;
(4) coarsening of social behaviour.
G4. For a confident clinical diagnosis, G1 should have been present for at least six months; if the period since the manifest onset is shorter,
the diagnosis can only be tentative.
Comments: The diagnosis is further supported by evidence of damage to other higher cortical functions, such as aphasia, agnosia, apraxia.
Judgment about independent living or the development of dependence (upon others) need to take account of the cultural expectation
and context.
Dementia is specified here as having a minimum duration of six months to avoid confusion with reversible states with identical behavioural
syndromes, such as traumatic subdural haemorrhage (S06.5), normal pressure hydrocephalus (G91.2) and diffuse or focal brain injury
(S06.2 and S06.3).
A fiHh character may be used to indicate the presence of additional symptoms, in the categories F00-F03
(F00 Dementia in Alzheimer's disease; F01 Vascular dementia; F02 Dementia in diseases classified elsewhere; and
F03 Unspecified dementia), as follows:
.x0 without additional symptoms
.x1 with other symptoms, predominantly delusional
.x2 with other symptoms, predominantly hallucinatory
.x3 with other symptoms, predominantly depressive
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
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.x4 with other mixed symptoms
A sixth character may be used to indicate the severity of the dementia:
.xx0 mild
.xx1 moderate
.xx2 severe
As mentioned above the overall severity of the dementia depends on the level of memory or intellectual impairment, whichever is the
more severe.
F00 DEMENTIA IN ALZHEIMER'S DISEASE
A. The general criteria for dementia (G1 to G4) must be met.
B. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia (e.g.
cerebrovascular disease, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus), a systemic disorder (e.g. hypothy-
roidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol- or drug-abuse.
Comments: The diagnosis is confirmed by post mortem evidence of neurofibrillary tangles and neuritic plaques in excess of those found
in normal ageing of the brain.
The following features support the diagnosis, but are not necessary elements: Involvement of cortical functions as evidenced by aphasia,
agnosia or apraxia; decrease of motivation and drive, leading to apathy and lack of spontaneity; irritability and disinhibition of social
behaviour; evidence from special investigations that there is cerebral atrophy, particularly if this can be shown to be increasing over time.
In severe cases there may be Parkinson-like extrapyramidal changes, logoclonia, and epileptic fits.
Specification of features for possible subtypes. Because of the possibility that subtypes exist, it is recommended that the following char-
acteristics be ascertained as a basis for a further classification: age at onset; rate of progression; the configuration of the clinical features,
particularly the relative prominence (or lack) of temporal, parietal or frontal lobe signs; any neuropathological or neurochemical abnor-
malities, and their pattern.
The division of AD into subtypes can at present be accomplished in two ways: first by taking only the age of onset and labelling AD as either
early or late, with an approximate cut-o= point at 65 years; or secondly, by assessing how well the individual conforms to one of the two
putative syndromes, early or late onset type. It should be noted that it is unlikely that a sharp distinction exists between early and late
onset type. Early onset type may occur in late life, just as late onset type may occasionally have an onset under the age of 65. The following
criteria may be used to differentiate F00.0 from F00.1, but it should be remembered that the status of this subdivision is still controversial.
F00.0 Dementia in Alzheimer's disease with early onset
1. The criteria for dementia in Alzheimer's disease (F00) must be met, and the age at onset being under 65 years.
2. In addition, at least one of the following requirements must be met:
(a) evidence of a relatively rapid onset and progression;
(b) in addition to memory impairment, there is aphasia (amnesic or sensory), agraphia, alexia, acalculia, or apraxia (indicating the presence
of temporal, parietal and/or frontal lobe involvement).
F00.1 Dementia in Alzheimer's disease with late onset
1. The criteria for dementia in Alzheimer's disease (F00) must be met and the age at onset must be 65 or more.
2. In addition, at least one of the following requirements must be met:
(a) evidence of a very slow, gradual onset and progression (the rate of the latter may be known only retrospectively after a course of 3
years or more);
(b) predominance of memory impairment G1.1, over intellectual impairment G1.2 (see general criteria for dementia).
F00.2 Dementia in Alzheimer's disease, atypical or mixed type
Use this term and code for dementias that have important atypical features or that fulfil criteria for both early and late onset type of
Alzheimer's disease. Mixed Alzheimer's and vascular dementia is also included here.
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F00.9 Dementia in Alzheimer's disease, unspecified
F01 VASCULAR DEMENTIA
G1. The general criteria for dementia (G1 to G4) must be met.
G2. Unequal distribution of deficits in higher cognitive functions, with some affected and others relatively spared. Thus memory may be
quite markedly affected while thinking, reasoning and information processing may show only mild decline.
G3. There is clinical evidence of focal brain damage, manifest as at least one of the following:
(1) unilateral spastic weakness of the limbs;
(2) unilaterally increased tendon reflexes;
(3) an extensor plantar response;
(4) pseudobulbar palsy.
G4. There is evidence from the history, examination, or tests, of a significant cerebrovascular disease, which may reasonably be judged to
be etiologically related to the dementia (e.g. a history of stroke; evidence of cerebral infarction).
The following criteria may be used to differentiate subtypes of vascular dementia, but it should be remembered that the usefulness of this
subdivision may not be generally accepted.
F01.0 Vascular dementia of acute onset
A. The general criteria for vascular dementia (F01) must be met.
B. The dementia develops rapidly (i.e. usually within one month, but within no longer than three months) after a succession of strokes,
or (rarely) after a single large infarction.
F01.1 Multi-infarct dementia
A. The general criteria for vascular dementia (F01) must be met.
B. The onset of the dementia is gradual (i.e. within three to six months), following a number of minor ischaemic episodes.
Comments: It is presumed that there is an accumulation of infarcts in the cerebral parenchyma. Between the ischaemic episodes there
may be periods of actual clinical improvement.
F01.2 Subcortical vascular dementia
A. The general criteria for vascular dementia (F01) must be met.
B. A history of hypertension.
C. Evidence from clinical examination and special investigations of vascular disease located in the deep white matter of the cerebral hemi-
spheres, with preservation of the cerebral cortex.
F01.3 Mixed cortical and subcortical vascular dementia
Mixed cortical and subcortical components of the vascular dementia may be suspected from the clinical features, the results of investiga-
tions (including autopsy), or both.
F01.8 Other vascular dementia
F01.9 Vascular dementia, unspecified
F02 DEMENTIA IN OTHER DISEASES CLASSIFIED ELSEWHERE
F02.0 Dementia in Pick's disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Slow onset with steady deterioration.
C. Predominance of frontal lobe involvement evidenced by two or more of the following:
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
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(1) emotional blunting;
(2) coarsening of social behaviour;
(3) disinhibition;
(4) apathy or restlessness;
(5) aphasia.
D. Relative preservation, in the early stages, of memory and parietal lobe functions.
F02.1 Dementia in Creutzfeldt-Jakob disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Very rapid progression of the dementia, with disintegration of virtually all higher cerebral functions.
C. The emergence, usually after or simultaneously with the dementia, of one or more of the following types of neurological symptoms
and signs:
(1) pyramidal symptoms;
(2) extrapyramidal symptoms;
(3) cerebellar symptoms;
(4) aphasia;
(5) visual impairment.
Comments: An akinetic and mute state is the typical terminal stage. An amyotrophic variant may be seen, where the neurological signs
precede the onset of the dementia. A characteristic electroencephalogram (periodic spikes against a slow and low voltage background), if
present in association with the above clinical signs, will increase the probability of the diagnosis. However, the diagnosis can be confirmed
only by neuropathological examination (neuronal loss, astrocytosis, and spongiform changes). Because of the risk of infection, this should
be carried out only under special protective conditions.
F02.2 Dementia in Huntington's disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Subcortical functions are affected first and dominate the picture of dementia throughout; manifest as slowness of thinking or movement
and personality alteration with apathy or depression.
C. Presence of involuntary choreiform movements, typically of the face, hands or shoulders, or in the gait. The patient may attempt to
conceal them by converting them into a voluntary action.
D. A history of Huntington's disease in one parent or a sibling; or a family history which suggests the disorder.
E. The absence of clinical features otherwise accounting for the abnormal movements.
Comments: In addition to involuntary choreiform movements there may be development of extrapyramidal rigidity or spasticity with
pyramidal signs.
F02.3 Dementia in Parkinson's disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Diagnosis of Parkinson's disease.
C. Absence of cognitive impairment attributable to anti-parkinsonian medication.
D. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia, including
other forms of brain disease, damage or dysfunction (e.g. cerebrovascular disease, HIV disease, Huntington's disease, normal pressure
hydrocephalus), a systemic disorder (e.g. hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol or drug abuse.
If criteria are also fulfilled for dementia in Alzheimer's disease with late onset (F00.1), this category F00.1 should be used in combination
with Parkinson's disease G20.
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F02.4 Dementia in human immunodeficiency (HIV) disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Diagnosis of HIV infection.
C. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia, including
other forms of brain disease, damage or dysfunction (e.g. Alzheimer's disease, cerebrovascular disease, Parkinson's disease, Huntington's
disease, normal pressure hydrocephalus), a systemic disorder (e.g. hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or
alcohol or drug abuse.
F02.8 Dementia in other specified diseases classified elsewhere
Dementia can occur as a manifestation or consequence of a variety of cerebral and somatic conditions. To specify the etiology, the ICD-10
code for the underlying condition should be added.
F03 UNSPECIFIED DEMENTIA
This category should be used when the general criteria for dementia are met, but when it is not possible to identify one of the specific
types (F00.0-F02.9).
Appendix 2. AD8 Informant Questionnaire
 
Remember, “Yes, a change” indicates that there has been a change in the last sever-
al years caused by cognitive (thinking and memory) problems.
YES
A change
NO
No change
N/A
Don’t know
1. Problems with judgment (e.g., problems making decisions, bad financial deci-
sions, problems with thinking)
     
2. Less interest in hobbies/activities      
3. Repeats the same things over and over (questions, stories, or statements)      
4. Trouble learning how to use a tool, appliance, or gadget (e.g., VCR, computer, mi-
crowave, remote control)
     
5. Forgets correct month or year      
6. Trouble handling complicated financial affairs (e.g. balancing checkbook, income
taxes, paying bills)
     
7. Trouble remembering appointments      
8. Daily problems with thinking and/or memory      
TOTAL AD8 SCORE  
 
 
Appendix 3. AD8 administration and scoring guidelines
A spontaneous self-correction is allowed for all responses without counting as an error.
The questions are given to the respondent on a clipboard for self–administration or can be read aloud to the respondent either in person
or over the phone. It is preferable to administer the AD8 to an informant, if available. If an informant is not available, the AD8 may be
administered to the patient.
When administered to an informant, specifically ask the respondent to rate change in the patient.
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
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When administered to the patient, specifically ask the patient to rate changes in his/her ability for each of the items, without attributing
causality.
If read aloud to the respondent, it is important for the clinician to carefully read the phrase as worded and give emphasis to note changes
due to cognitive problems (not physical problems).
There should be a one second delay between individual items.
No timeframe for change is required.
The final score is a sum of the number items marked “Yes, A change”.
Appendix 4. Commonly used cognitive assessments/screening tools
 
TEST Cochrane DTA review in process
Mini-mental state examination (MMSE) YES
GPcog YES
Minicog YES
Memory Impairment Screen (MIS) Still available
Abbreviated mental testing Still available
Clock drawing tests (CDT) Still available
Montreal Cognitive Assessment (MoCA) YES
IQCODE (informant interview) YES
 
 
For each test, the planned review will encompass diagnostic test accuracy in community; primary and secondary care settings.
Appendix 5. Search Strategy for use with MEDLINE electronic database
 
MEDLINE In-process and oth-
er non-indexed citations and
MEDLINE 1950-present (Ovid
SP)
1. AD8.ti,ab.
2. "informant questionnaire on cognitive decline".ti,ab.
3. "Alzheimer’s Disease eight question screen".ti,ab.
4. "AD 8".ti,ab.
5. ("informant* questionnair*" adj3 (dement* or screening)).ti,ab.
6. ("screening test*" adj2 (dement* or alzheimer*)).ti,ab.
7. or/1-6
 
 
 
Appendix 6. Search strategy (MEDLINE Ovid SP) run for specialised register (ALOIS)
Search narrative: The searches detailed above are very simple, essentially single concept strategies based on the index test (AD8). This is
a sensitive approach to take. More complex and developed searches are run each month for the dementia group.
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Every month the following strategy is run in Medline (via Ovid SP). The results are screened based on a reading of title and abstract. The
full texts (where there is one) are then obtained and a few key details about each study are extracted including Index test/s and details of
population and setting. For this review it was expected that most studies would be identified through a search of multiple sources based
on one concept (the index test in question). However, we felt it was worth also searching ALOIS for any studies which had evaluated the
accuracy of AD8 but had not referred to it in the bibliographic details of the reference.
 
MEDLINE In-process and oth-
er non-indexed citations and
MEDLINE 1950-present (Ovid
SP)
1. "word recall".ti,ab.
2. "7-minute screen".ti,ab.
3. "6 item cognitive impairment test".ti,ab.
4. "6 CIT".ti,ab.
5. "AB cognitive screen".ti,ab.
6. "abbreviated mental test".ti,ab.
7. "ADAS-cog".ti,ab.
8. AD8.ti,ab.
9. "inform* interview".ti,ab.
10. "animal fluency test".ti,ab.
11. "brief alzheimer* screen".ti,ab.
12. "brief cognitive scale".ti,ab.
13. "clinical dementia rating scale".ti,ab.
14. "clinical dementia test".ti,ab.
15. "community screening interview for dementia".ti,ab.
16. "cognitive abilities screening instrument".ti,ab.
17. "cognitive assessment screening test".ti,ab.
18. "cognitive capacity screening examination".ti,ab.
19. "clock drawing test".ti,ab.
20. "deterioration cognitive observee".ti,ab.
21. "Dem Tect".ti,ab.
22. "fuld object memory evaluation".ti,ab.
23. "IQCODE".ti,ab.
24. "mattis dementia rating scale".ti,ab.
25. "memory impairment screen".ti,ab.
26. "minnesota cognitive acuity screen".ti,ab.
27. "mini-cog".ti,ab.
28. "mini-mental state exam*".ti,ab.
29. "mmse".ti,ab.
30. "modified mini-mental state exam".ti,ab.
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31. "3MS".ti,ab.
32. "neurobehavioural cognitive status exam*".ti,ab.
33. "cognistat".ti,ab.
34. "quick cognitive screening test".ti,ab.
35. "QCST".ti,ab.
36. "rapid dementia screening test".ti,ab.
37. "RDST".ti,ab.
38. "repeatable battery for the assessment of neuropsychological status".ti,ab.
39. "RBANS".ti,ab.
40. "rowland universal dementia assessment scale".ti,ab.
41. "rudas".ti,ab.
42. "self-administered gerocognitive exam*".ti,ab.
43. ("self-administered" and "SAGE").ti,ab.
44. "self-administered computerized screening test for dementia".ti,ab.
45. "short and sweet screening instrument".ti,ab.
46. "sassi".ti,ab.
47. "short cognitive performance test".ti,ab.
48. "syndrome kurztest".ti,ab.
49. "six item screener".ti,ab.
50. "short memory questionnaire".ti,ab.
51. ("short memory questionnaire" and "SMQ").ti,ab.
52. "short orientation memory concentration test".ti,ab.
53. "s-omc".ti,ab.
54. "short blessed test".ti,ab.
55. "short portable mental status questionnaire".ti,ab.
56. "spmsq".ti,ab.
57. "short test of mental status".ti,ab.
58. "telephone interview of cognitive status modified".ti,ab.
59. "tics-m".ti,ab.
60. "trail making test".ti,ab.
61. "verbal fluency categories".ti,ab.
62. "WORLD test".ti,ab.
63. "general practitioner assessment of cognition".ti,ab.
64. "GPCOG".ti,ab.
  (Continued)
AD-8 for diagnosis of dementia across a variety of healthcare settings (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
65. "Hopkins verbal learning test".ti,ab.
66. "HVLT".ti,ab.
67. "time and change test".ti,ab.
68. "modified world test".ti,ab.
69. "symptoms of dementia screener".ti,ab.
70. "dementia questionnaire".ti,ab.
71. "7MS".ti,ab.
72. ("concord informant dementia scale" or CIDS).ti,ab.
73. (SAPH or "dementia screening and perceived harm*").ti,ab.
74. or/1-73
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/ OR Cognition Disorders/ OR Memory Disor-
ders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. ("lewy bod*" or DLB or LBD).ti,ab.
81. "cognit* impair*".ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function*)).ti,ab.
83. (memory adj3 (complain* or declin* or function*)).ti,ab.
84. or/75-83
85. exp "sensitivity and specificity"/
86. "reproducibility of results"/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
95. specificit*.ab.
96. (ROC or "receiver operat*").ab.
97. Area under curve/
98. ("Area under curve" or AUC).ab.
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99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab.
106. or/85-105
107. exp dementia/di OR Delirium, Dementia, Amnestic, Cognitive Disorders/di
108. Cognition Disorders/di
109. Memory Disorders/di
110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. "neuropsychological test*".ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab.
118. (neuropsychological adj (assess* or evaluat* or test* or exam* or battery)).ti,ab.
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. (animals not (humans and animals)).sh.
131. 129 not 130
The concepts for this are:
  (Continued)
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A Specific neuropsychological tests
B General terms (both free text and MeSH) for tests/testing/screening
C Outcome: dementia diagnosis (unfocused MeSH with diagnostic sub-headings)
D Condition of interest: Dementia (general dementia terms both free text and MeSH – exploded and
unfocused)
E Methodological filter: not used to limit all search
The concept combinations are:
1. (A OR B) AND C
2. (A OR B) AND D AND E
3. A AND E
  (Continued)
 
Appendix 7. Assessment of reporting quality - STARD checklist
 
Section and Top-
ic
   
TITLE/ABSTRACT
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitiv-
ity and specificity').
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or
comparing accuracy between tests or across participant groups.
METHODS    
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations where
data were collected.
  4 Participant recruitment: Was recruitment based on presenting symptoms, results from
previous tests, or the fact that the participants had received the index tests or the refer-
ence standard?
  5 Participant sampling: Was the study population a consecutive series of participants de-
fined by the selection criteria in item 3 and 4? If not, specify how participants were further
selected.
  6 Data collection: Was data collection planned before the index test and reference standard
were performed (prospective study) or after (retrospective study)?
Test methods 7 The reference standard and its rationale.
  8 Technical specifications of material and methods involved including how and when mea-
surements were taken, and/or cite references for index tests and reference standard.
  9 Definition of and rationale for the units, cut-o=s and/or categories of the results of the in-
dex tests and the reference standard.
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  10 The number, training and expertise of the persons executing and reading the index tests
and the reference standard.
  11 Whether or not the readers of the index tests and reference standard were blind (masked)
to the results of the other test and describe any other clinical information available to the
readers.
Statistical meth-
ods
12 Methods for calculating or comparing measures of diagnostic accuracy, and the statisti-
cal methods used to quantify uncertainty (e.g. 95% confidence intervals).
  13 Methods for calculating test reproducibility, if done.
RESULTS    
Participants 14 When study was performed, including beginning and end dates of recruitment.
  15 Clinical and demographic characteristics of the study population (at least information on
age, gender, spectrum of presenting symptoms).
  16 The number of participants satisfying the criteria for inclusion who did or did not undergo
the index tests and/or the reference standard; describe why participants failed to under-
go either test (a flow diagram is strongly recommended).
Test results 17 Time-interval between the index tests and the reference standard, and any treatment ad-
ministered in between.
  18 Distribution of severity of disease (define criteria) in those with the target condition; oth-
er diagnoses in participants without the target condition.
  19 A cross tabulation of the results of the index tests (including indeterminate and missing
results) by the results of the reference standard; for continuous results, the distribution of
the test results by the results of the reference standard.
  20 Any adverse events from performing the index tests or the reference standard.
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confi-
dence intervals).
  22 How indeterminate results, missing data and outliers of the index tests were handled.
  23 Estimates of variability of diagnostic accuracy between subgroups of participants, read-
ers or centres, if done.
  24 Estimates of test reproducibility, if done.
DISCUSSION 25 Discuss the clinical applicability of the study findings.
  (Continued)
 
Appendix 8. Assessment of methodological quality table QUADAS-2 tool
 
DOMAIN PATIENT SELEC-
TION
INDEX TEST REFERENCE STANDARD FLOW AND
TIMING
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Description Describe meth-
ods of patient
selection: De-
scribe included
patients (prior
testing, presen-
tation, intended
use of index test
and setting):
Describe the index test
and how it was con-
ducted and interpreted:
Describe the reference standard and how
it was conducted and interpreted:
Describe any
patients who
did not receive
the index test(s)
and/or refer-
ence standard
or who were ex-
cluded from the
2x2 table (re-
fer to flow dia-
gram): Describe
the time inter-
val and any in-
terventions be-
tween index
test(s) and ref-
erence stan-
dard:
Was a consecu-
tive or random
sample of pa-
tients enrolled?
Were the index test re-
sults interpreted with-
out knowledge of the
results of the reference
standard?
Is the reference standard likely to correct-
ly classify the target condition?
Was there an
appropriate in-
terval between
index test(s)
and reference
standard?
Was a case-
control design
avoided?
Did all patients
receive a refer-
ence standard?
Did all patients
receive the
same reference
standard?
Signalling questions
(yes/no/unclear)
Did the study
avoid inappro-
priate exclu-
sions?
If a threshold was used,
was it pre-specified?
Were the reference standard results inter-
preted without knowledge of the results
of the index test?
Were all pa-
tients included
in the analysis?
Risk of bias: High/
low/ unclear
Could the selec-
tion of patients
have introduced
bias?
Could the conduct or
interpretation of the
index test have intro-
duced bias?
Could the reference standard, its con-
duct, or its interpretation have intro-
duced bias?
Could the pa-
tient flow have
introduced
bias?
Concerns regarding
applicability: High/
low/ unclear
Are there con-
cerns that the in-
cluded patients
do not match the
review question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that the target condi-
tion as defined by the reference standard
does not match the review question?
 
  (Continued)
 
Appendix 9. Anchoring statements for quality assessment of AD-8 diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of AD-8 in dementia. These state-
ments are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus group.Davis 2013
During the focus group and the piloting/validation of this guidance, it was clear that certain issues were key to assessing quality, while other
issues were important to record but less important for assessing overall quality. To assist, we describe a system wherein certain items can
dominate. For these dominant items, if scored “high risk” then that section of the QUADAS-2 results table is likely to be scored as high risk
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of bias regardless of other scores. For example, in dementia diagnostic test accuracy studies, ensuring that clinicians performing dementia
assessment are blinded to results of index test is fundamental. If this blinding was not present then the item on reference standard should
be scored “high risk of bias”, regardless of the other contributory elements.
We have detailed how QUADAS-2 has been operationalised for use with dementia reference standard studies below. In these descriptors
dominant items are labelled as "high risk of bias for total section regardless of other items".
In assessing individual items, the score of unclear should only be given if there is genuine uncertainty. In these situations review authors
will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Selection
Was a case-control or similar design avoided?
Designs similar to case-control that may introduce bias are those designs where the study team deliberately increase or decrease the
proportion with the target condition. For example, a population study may be enriched with extra dementia patients from a secondary
care setting. Such studies will be automatically labelled high risk of bias and this will be assessed as a potential source of heterogeneity.
If case-control is used then grading will be high risk of bias for total section regardless of other items (in fact case-control studies will not
be included in this review).
Was the sampling method appropriate?
Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that is based on
volunteers or selecting participants from a clinic or research resource is prone to bias.
Are exclusion criteria described and appropriate?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions
are detailed, the study will be graded as low risk of bias if exclusions are felt to be appropriate by the review authors. Certain exclusions
common to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric diag-
nosis; other neurodegenerative condition.
Post hoc exclusions will be labelled high risk of bias for total section regardless of other items.
Index Test
Was AD-8 assessment performed without knowledge of clinical dementia diagnosis?
Terms such as “blinded” or “independently and without knowledge of” are sufficient and full details of the blinding procedure are not
required. This item may be scored as low risk of bias if explicitly described or if there is a clear temporal pattern to order of testing that
precludes the need for formal blinding i.e. all AD-8 assessments performed before dementia assessment.
If there is no attempt at blinding grading will be high risk of bias for total section regardless of other items.
Were AD-8 thresholds prespecified?
For scales there is often a reference point (in units or categories) above which participants are classified as “test positive”; this may be
referred to as threshold; clinical cut-o= or dichotomisation point. A study is classified high risk of bias if the authors define the optimal cut-
o= post-hoc based on their own study data. Certain papers may use an alternative methodology for analysis that does not use thresholds
and these papers should be classified as low risk of bias.
Were su"icient data on AD-8 application given for the test to be repeated in an independent study?
Particular points of interest for AD-8 include method of administration (for example, self-completed questionnaire versus direct question-
ing interview); nature of informant; language of assessment. If a novel form of AD-8 is used, details of the scale should be included or a
reference given to an appropriate descriptive text. Where AD-8 is used in a novel manner, for example, a translated questionnaire, there
should be evidence of validation work.
Reference Standard
Is the assessment used for clinical diagnosis of dementia acceptable?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and ICD-10. Criteria
specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s dementia; McKeith criteria for Lewy
Body dementia; Lund criteria for frontotemporal dementias; and the NINDS-AIREN criteria for vascular dementia. Where the criteria used
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for assessment are not familiar to the review authors or the Cochrane Dementia and Cognitive Improvement Group this item should be
classified as high risk of bias.
Was clinical assessment for dementia performed without knowledge of AD-8?
Terms such as “blinded” or “independent” are sufficient and full details of the blinding procedure are not required. This may be scored
as low risk of bias if explicitly described or if there is a clear temporal pattern to order of testing, i.e. all dementia assessments performed
before AD-8 testing.
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing is
a usual component of clinical assessment for dementia, however, specific use of the scale under review in the clinical dementia assessment
should be scored as high risk of bias. We have prespecified that dementia diagnosis that explicitly uses AD-8 will be classified as high risk
of bias for total section regardless of other items.
Were su"icient data on dementia assessment method given for the assessment to be repeated in an independent study?
The criteria used for clinical assessment are discussed in another item. Particular points of interest for dementia assessment include the
background of the assessor, training/expertise of the assessor; additional information available to inform diagnosis (neuroimaging; neu-
ropsychological testing).
Flow
Was there an appropriate interval between AD-8 and clinical dementia assessment?
For a cross-sectional study design, there is potential for change between assessments. The ideal would be same day assessment but this
is not always feasible. We have set an arbitrary maximum interval of one month between tests, although this may be revised depending
on the test and the stability of the condition of interest.
For a study looking at delayed verification there is no agreement on how long the interval should be between index test and first/last
assessment for dementia. An interval of less than six months is unlikely to be sufficient time for progression.
Did all get the same assessment for dementia regardless of AD-8 result?
There may be scenarios where only those who score “test positive” on AD-8 have a more detailed assessment. Where dementia assessment
(or other reference standard) differs depending on the AD-8 result this should be classified as high risk of bias.
Were all who received AD-8 assessment included in the final analysis?
If the study has drop outs these should be accounted for; a maximum proportion of drop outs to remain low risk of bias has been specified
as 20%.
Were missing AD-8 results or un-interpretable AD-8 results reported?
Where missing results are reported if there is substantial attrition (we have set an arbitrary value of 50% missing data) this should be scored
as high risk of bias for total section regardless of other items.
Applicability
Were those included representative of the general population of interest?
Those included should match the intended population as described in the review question. If not already specified in the review inclusion
criteria, setting will be particularly important – the review authors should consider population in terms of symptoms; pre-testing; potential
disease prevalence. Studies that use very selected groups or subgroups will be classified as poor applicability.
Was AD-8 performed consistently and in a manner similar to its use in clinical practice?
AD-8 studies will be judged against the original description of its use.
Was clinical diagnosis of dementia (or other reference standard) made in a manner similar to current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have assessed the dementia diagnosis. For certain reviews
an applicability statement relating to reference standard may not be applicable. There is the possibility that a form of dementia assess-
ment, although valid, may diagnose a far larger proportion with disease than would be seen in usual clinical practice. In this instance the
item should be rated poor applicability.
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